Starpharma’s DEP^® platform is highly versatile, which means it can be applied to a wide range of therapies and types of molecules, including small-molecule drugs, peptides, antibodies, and radioisotopes. This flexibility has allowed Starpharma to extend its research programs and capabilities into the area of radiodiagnostics and radiotherapeutics.

Starpharma has a number of programs in the area of DEP^® radiopharmaceuticals, involving both DEP^® radiodiagnostics and DEP^® radiotherapeutics.

DEP® HER2 Radiodiagnostic 

Starpharma's DEP^® HER2 Radiodiagnostic is a pre-clinical-stage radiodiagnostic product designed to specifically diagnose, stage, and monitor HER2-positive (HER2+) cancers with greater sensitivity, meaning patients suffering from these cancers could be diagnosed earlier, more accurately, and monitored more closely during cancer treatment. 

DEP® HER2 Radiotherapeutic 

Starpharma's DEP^® HER2 Radiotherapeutic is a pre-clinical-stage radiotherapeutic product designed to selectively penetrate and accumulate within HER2+ tumours and more effectively deliver radiation to kill tumour cells that may be unreachable by conventional therapies. 

Benefits of Starpharma’s DEP^® technology in radiopharmaceuticals

Applying Starpharma’s DEP^® technology to radiotheranostics has the potential to provide a number of therapeutic and commercial benefits, including:

• Flexible size and structure
• Enhanced tumour accumulation due to enhanced permeability and retention (EPR) effect
• Enhanced efficacy through tissue targeting and retention due to specific receptor binding
• Reduced off-target toxicities